|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lau WY and Lai EC: Hepatocellular
carcinoma: Current management and recent advances. Hepatobiliary
Pancreat Dis Int. 7:237–257. 2008.PubMed/NCBI
|
|
3
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM: Updated treatment approach to
hepatocellular carcinoma. J Gastroenterol. 40:225–235. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sato M, Tateishi R, Yasunaga H, Horiguchi
H, Yoshida H, Matsuda S and Koike K: Mortality and morbidity of
hepatectomy, radiofrequency ablation, and embolization for
hepatocellular carcinoma: A national survey of 54,145 patients. J
Gastroenterol. 47:1125–1133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu ZY and Zheng Z: An optimized 3-step
strategy for preventing and treating post-operation relapse and
metastasis of malignant tumors with traditional Chinese medicine.
Zhong Xi Yi Jie He Xue Bao. 5:5–10. 2007.(In Chinese). View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu X, Zhao H, Yang H, Mao Y, Sang X, Miao
R, Xu Y, Du S, Xu H, Chi T, et al: A prospective clinical study on
early recurrence of hepatocellular carcinoma after hepatectomy. J
Surg Oncol. 100:488–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye
QH, Wang L, Zhou J, Qiu SJ, Li Y, et al: A decade's studies on
metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol.
130:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhowmick NA, Neilson EG and Moses HL:
Stromal fibroblasts in cancer initiation and progression. Nature.
432:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang JD, Nakamura I and Roberts LR: The
tumor microenvironment in hepatocellular carcinoma: Current status
and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Spano D and Zollo M: Tumor
microenvironment: A main actor in the metastasis process. Clin Exp
Metastasis. 29:381–395. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Wang JN, Tang JM, Kong X, Yang
JY, Zheng F, Guo LY, Huang YZ, Zhang L, Tian L, et al: VEGF is
essential for the growth and migration of human hepatocellular
carcinoma cells. Mol Biol Rep. 39:5085–5093. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gocheva V, Zeng W, Ke D, Klimstra D,
Reinheckel T, Peters C, Hanahan D and Joyce JA: Distinct roles for
cysteine cathepsin genes in multistage tumorigenesis. Genes Dev.
20:543–556. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brömme D, Bonneau PR, Lachance P,
Wiederanders B, Kirschke H, Peters C, Thomas DY, Storer AC and
Vernet T: Functional expression of human cathepsin S in
Saccharomyces cerevisiae. Purification and characterization
of the recombinant enzyme. J Biol Chem. 268:4832–4838.
1993.PubMed/NCBI
|
|
16
|
Levicar N, Strojnik T, Kos J, Dewey RA,
Pilkington GJ and Lah TT: Lysosomal enzymes, cathepsins in brain
tumour invasion. J Neurooncol. 58:21–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang B, Sun J, Kitamoto S, Yang M, Grubb
A, Chapman HA, Kalluri R and Shi GP: Cathepsin S controls
angiogenesis and tumor growth via matrix-derived angiogenic
factors. J Biol Chem. 281:6020–6029. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu J, Li D, Ke Z, Liu R, Maubach G and
Zhuo L: Cathepsin S is aberrantly overexpressed in human
hepatocellular carcinoma. Mol Med Rep. 2:713–718. 2009.PubMed/NCBI
|
|
19
|
Sevenich L, Schurigt U, Sachse K, Gajda M,
Werner F, Müller S, Vasiljeva O, Schwinde A, Klemm N, Deussing J,
et al: Synergistic antitumor effects of combined cathepsin B and
cathepsin Z deficiencies on breast cancer progression and
metastasis in mice. Proc Natl Acad Sci USA. 107:2497–2502. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fernández PL, Farré X, Nadal A, Fernández
E, Peiró N, Sloane BF, Shi GP, Chapman HA, Campo E and Cardesa A:
Expression of cathepsins B and S in the progression of prostate
carcinoma. Int J Cancer. 95:51–55. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ferrara N: Role of vascular endothelial
growth factor in physiologic and pathologic angiogenesis:
Therapeutic implications. Semin Oncol. 29(6 Suppl 16): 10–14. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan Q, Wang X, Zhang H, Li C, Fan J and Xu
J: Silencing cathepsin S gene expression inhibits growth, invasion
and angiogenesis of human hepatocellular carcinoma in vitro.
Biochem Biophys Res Commun. 425:703–710. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shibuya M: Vascular Endothelial Growth
Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A
Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes
Cancer. 2:1097–1105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roy H, Bhardwaj S and Ylä-Herttuala S:
Biology of vascular endothelial growth factors. FEBS Lett.
580:2879–2887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaseb AO, Hanbali A, Cotant M, Hassan MM,
Wollner I and Philip PA: Vascular endothelial growth factor in the
management of hepatocellular carcinoma: A review of literature.
Cancer. 115:4895–4906. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF,
Chang KY, Huang WC, Lin PW, Chiang CW and Chang TT: Hepatitis B
virus X protein upregulates mTOR signaling through IKKbeta to
increase cell proliferation and VEGF production in hepatocellular
carcinoma. PLoS One. 7:e419312012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Waldner MJ and Neurath MF: Targeting the
VEGF signaling pathway in cancer therapy. Expert Opin Ther Targets.
16:5–13. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boman HG, Wade D, Boman IA, Wåhlin B and
Merrifield RB: Antibacterial and antimalarial properties of
peptides that are cecropin-melittin hybrids. FEBS Lett.
259:103–106. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jang HS, Kim SK, Han JB, Ahn HJ, Bae H and
Min BI: Effects of bee venom on the pro-inflammatory responses in
RAW264.7 macrophage cell line. J Ethnopharmacol. 99:157–160. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jo M, Park MH, Kollipara PS, An BJ, Song
HS, Han SB, Kim JH, Song MJ and Hong JT: Anti-cancer effect of bee
venom toxin and melittin in ovarian cancer cells through induction
of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol
Appl Pharmacol. 258:72–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JD, Kim SY, Kim TW, Lee SH, Yang HI,
Lee DI and Lee YH: Anti-inflammatory effect of bee venom on type II
collagen-induced arthritis. Am J Chin Med. 32:361–367. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park HJ, Lee HJ, Choi MS, Son DJ, Song HS,
Song MJ, Lee JM, Han SB, Kim Y and Hong JT: JNK pathway is involved
in the inhibition of inflammatory target gene expression and
NF-kappaB activation by melittin. J Inflamm (Lond). 5:72008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chu ST, Cheng HH, Huang CJ, Chang HC, Chi
CC, Su HH, Hsu SS, Wang JL, Chen IS, Liu SI, et al: Phospholipase
A2-independent Ca2+ entry and subsequent apoptosis induced by
melittin in human MG63 osteosarcoma cells. Life Sci. 80:364–369.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li B, Gu W, Zhang C, Huang XQ, Han KQ and
Ling CQ: Growth arrest and apoptosis of the human hepatocellular
carcinoma cell line BEL-7402 induced by melittin. Onkologie.
29:367–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu S, Yu M, He Y, Xiao L, Wang F, Song C,
Sun S, Ling C and Xu Z: Melittin prevents liver cancer cell
metastasis through inhibition of the Rac1-dependent pathway.
Hepatology. 47:1964–1973. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huh JE, Kang JW, Nam D, Baek YH, Choi DY,
Park DS and Lee JD: Melittin suppresses VEGF-A-induced tumor growth
by blocking VEGFR-2 and the COX-2-mediated MAPK signaling pathway.
J Nat Prod. 75:1922–1929. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gajski G and Garaj-Vrhovac V: Melittin: A
lytic peptide with anticancer properties. Environ Toxicol
Pharmacol. 36:697–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J,
Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, et al: Deficiency of
the cysteine protease cathepsin S impairs microvessel growth. Circ
Res. 92:493–500. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee TK, Cheung VC, Lu P, Lau EY, Ma S,
Tang KH, Tong M, Lo J and Ng IO: Blockade of CD47-mediated
cathepsin S/protease-activated receptor 2 signaling provides a
therapeutic target for hepatocellular carcinoma. Hepatology.
60:179–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu H, Chen D, Li Y and Zhang X: Effect of
polypeptides in bee venom on growth inhibition and apoptosis
induction of the human hepatoma cell line SMMC-7721 in-vitro
and Balb/c nude mice in-vivo. J Pharm Pharmacol. 58:83–89.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yusuf N, Irby C, Katiyar SK and Elmets CA:
Photoprotective effects of green tea polyphenols. Photodermatol
Photoimmunol Photomed. 23:48–56. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Flannery T, Gibson D, Mirakhur M, McQuaid
S, Greenan C, Trimble A, Walker B, McCormick D and Johnston PG: The
clinical significance of cathepsin S expression in human
astrocytomas. Am J Pathol. 163:175–182. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mohamed MM and Sloane BF: Cysteine
cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer.
6:764–775. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Quesada AR, Muñoz-Chápuli R and Medina MA:
Anti-angiogenic drugs: From bench to clinical trials. Med Res Rev.
26:483–530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song CC, Lu X, Cheng BB, Du J, Li B and
Ling CQ: Effects of melittin on growth and angiogenesis of human
hepatocellular carcinoma BEL-7402 cell xenografts in nude mice. Ai
Zheng. 26:1315–1322. 2007.(In Chinese). PubMed/NCBI
|
|
47
|
Huh JE, Lee EO, Kim MS, Kang KS, Kim CH,
Cha BC, Surh YJ and Kim SH: Penta-O-galloyl-beta-D-glucose
suppresses tumor growth via inhibition of angiogenesis and
stimulation of apoptosis: Roles of cyclooxygenase-2 and
mitogen-activated protein kinase pathways. Carcinogenesis.
26:1436–1445. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Toomey DP, Murphy JF and Conlon KC: COX-2,
VEGF and tumour angiogenesis. Surgeon. 7:174–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lu N, Gao Y, Ling Y, Chen Y, Yang Y, Gu
HY, Qi Q, Liu W, Wang XT, You QD and Guo QL: Wogonin suppresses
tumor growth in vivo and VEGF-induced angiogenesis through
inhibiting tyrosine phosphorylation of VEGFR2. Life Sci.
82:956–963. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huh JE, Baek YH, Lee MH, Choi DY, Park DS
and Lee JD: Bee venom inhibits tumor angiogenesis and metastasis by
inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing
mice. Cancer Lett. 292:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
